Related Experiment Video
Updated: May 12, 2026
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors
Katherine L Jameson1,2, Pawel K Mazur3,4, Ashley M Zehnder1,2
1Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California, USA.
Nature Medicine
|April 23, 2013
Summary
Targeting cancer by disrupting the IQ motif-containing GTPase activating protein 1 (IQGAP1) scaffold that regulates the ERK1 and ERK2 (ERK1/2) mitogen-activated protein kinase (MAPK) cascade offers a novel therapeutic strategy. This approach bypasses resistance to direct kinase inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The ERK1 and ERK2 (ERK1/2) mitogen-activated protein kinase (MAPK) cascade is upregulated in over 30% of cancers, often driven by mutations in KRAS or BRAF.
- Direct inhibition of MAPK pathway kinases faces challenges due to acquired resistance and essential roles in normal cell function.
- MAPK pathway scaffolds, like IQ motif-containing GTPase activating protein 1 (IQGAP1), regulate signal transmission and present an alternative therapeutic target.
Purpose of the Study:
- To investigate the role of IQGAP1 as a scaffold in RAS-driven tumorigenesis.
- To evaluate the therapeutic potential of disrupting IQGAP1-ERK1/2 interactions.
- To assess if targeting IQGAP1 can overcome resistance to existing MAPK inhibitors.
Main Methods:
- Investigated IQGAP1's role in RAS-driven tumorigenesis using mouse and human tissues.
- Developed and utilized an IQGAP1 WW domain peptide to disrupt IQGAP1-ERK1/2 interactions.
- Assessed the efficacy of the peptide in inhibiting tumorigenesis and overcoming resistance to BRAF inhibitors in preclinical models.
Main Results:
- IQGAP1 is essential for RAS-driven tumorigenesis in both mouse and human tissues.
- Disruption of IQGAP1-ERK1/2 interactions using a specific peptide inhibited RAS- and RAF-driven tumorigenesis.
- The IQGAP1-targeting peptide demonstrated efficacy against acquired resistance to vemurafenib and improved survival in tumor-bearing mice.
Conclusions:
- Disrupting MAPK scaffold-kinase interactions is a viable therapeutic strategy distinct from direct kinase inhibition.
- Targeting IQGAP1 offers a promising approach to overcome resistance mechanisms in MAPK-driven cancers.
- Systemically deliverable IQGAP1-targeting agents hold potential for cancer therapy.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...